Straits Times Index
3,285.73 -2.02 (-0.06%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,704.91 +420.37 (+2.43%) FTSE 100
8,078.86 +38.48 (+0.48%) Bitcoin USD
64,376.44 +106.78 (+0.17%) CMC Crypto 200
1,388.21 -8.33 (-0.60%)
REGENXBIO Inc. (RGNX)
After hours:
- PR Newswire
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 29, 2024.
- Simply Wall St.
REGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measures
Key Insights Significantly high institutional ownership implies REGENXBIO's stock price is sensitive to their trading...
- PR Newswire
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
REGENXBIO Inc. (Nasdaq: RGNX) today announced the publication of results from the Phase I/IIa trial evaluating the safety and tolerability of a single dose of subretinal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (wet AMD). Two-year data were published in The Lancet in a paper titled "Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study." These positive study results informed the ongoing pi
